chad3-ebo-z
Vaccineexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 20, 2015 (NCT02344407)
Timeline
Indications
Mechanism of action
- MarburgvirusImmunity, active
Marburgvirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- chad3-ebo z
- chad3-ebo-z
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03583606 | Phase 1 | Oct 11, 2018 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT02495246 | Phase 1 | Sep 21, 2015 | University of Oxford |
| NCT02485912 | Phase 1 | Jul 1, 2015 | Centre Hospitalier Universitaire le Dantec, University of Oxford |
| NCT02451891 | Phase 1 | Apr 1, 2015 | University of Oxford |
| NCT02344407 | Phase 2 | Jan 20, 2015 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Oxford | Academic/Hospital | 3 | 3 | 1 | 2015 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 2 | 2015 |
| Centre Hospitalier Universitaire le Dantec | Academic/Hospital | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1